Female After Care Daily
Testo originale in francese.
Prodotto naturale per la salute autorizzato in Canada
Se questo prodotto fosse venduto in Francia
- Dose déclarée au-delà d'une limite
Zinc: fino a 50 mg al giorno secondo la posologia pubblicata da Health Canada (2 unités posologiques par jour au plus, pour les adultes), oltre la dose massima di 15 mg fissata in Francia per un integratore alimentare (decreto del 2006, non rivisto dal novembre 2006).
arrêté du 9 mai 2006, annexe III. Decreti francesi del 9 maggio 2006 e del 14 novembre 2006 come pubblicati nella Gazzetta ufficiale (dosi giornaliere massime), consultato il 21 ottobre 2026.
- À vérifier
Zinc: fino a 50 mg al giorno secondo la posologia pubblicata da Health Canada, oltre il limite di sicurezza dell’EFSAAutorità europea per la sicurezza alimentare. per adulti (25 mg al giorno). Il riferimento dell’EFSA riguarda l’assunzione totale di una giornata, alimentazione e integratori.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (versione 11, agosto 2025), consultato il 21 ottobre 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte | Massimo giornaliero, adulto |
|---|---|---|
| Vitamine C Fonte : Acide ascorbique | 15 mg | 30.000 µg |
| Calcium Fonte : Calcium carbonate | 12,5 mg | 25.000 µg |
| Vitex agnus-castus Fonte : Fruit Estratto : Matériel brut sec Rapporto di estrazione : 10:1 Equivalente di pianta secca : 500 mg | 50 mg | Non calcolata |
| Folate Fonte : Acide folique | 0,2 Microgrammes | Non calcolata |
| Vitamine E Fonte : Acétate de dl-alpha tocophéryle | 10 mg AT | Non calcolata |
| Rubus idaeus Fonte : Feuille Estratto : Matériel brut sec Rapporto di estrazione : 10:1 Equivalente di pianta secca : 500 mg | 50 mg | Non calcolata |
| Vitamine B12 Fonte : Hydroxocobalamine | 25 Microgrammes | Non calcolata |
| Actaea racemosa Fonte : Racine et rhizome Estratto : Matériel brut sec Rapporto di estrazione : 30:1 Equivalente di pianta secca : 750 mg | 25 mg | Non calcolata |
| Vitamine A Fonte : Palmitate de vitamine A | 82,5 microgram RAE | Non calcolata |
| Niacine Fonte : Niacinamide | 15 mg | Non calcolata |
| Withania somnifera Fonte : Racine Estratto : Matériel brut sec Rapporto di estrazione : 10:1 Equivalente di pianta secca : 1.000 mg | 100 mg | Non calcolata |
| Zinc Fonte : Oxyde de zinc | 25 mg | 50.000 µg |
Ingredienti non medicinali
Cellulose microcristalline, Dioxyde de silicium, Gélatine, Stéarate de magnésium
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
| Adultes | minimum : 19 ans | 1 Capsule | 2 Tous les jours |
Usi autorizzati in Canada
Helps to support/promote healthy estrogen metabolism/balance. Helps in wound healing and connective tissue formation. Chaste Berry is used in Herbal Medicine (as a hormone normalizer) to help stabilize menstrual cycle irregularities and relieve premenstrual symptoms. Ashwagandha is traditionally used in Ayurveda as Rasayana (rejuvenative tonic). Ashwagandha is traditionally used in Ayurveda to relieve general debility, especially during convalescence or old age. Black Cohosh is used in Herbal Medicine to help relieve the pain associated with menstruation as well as premenstrual symptoms. Black Cohosh is traditionally used in Herbal Medicine to help ease nervous tension (calmative). Helps to maintain immune function. Helps to maintain the body's ability to metabolize nutrients. Source of vitamins and minerals, factors in the maintenance of good health. Source of vitamins and minerals, factors in normal growth and development. Source of vitamins and minerals to support biological functions which play a key role in the maintenance of good health. Source of antioxidant that helps to protect cell against the oxidative damage caused by free radicals.
Testo originale in inglese.
Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Cautions and Warnings : Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner. Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy. Do not take if you have or have a history of ovarian, uterine breast or non-melanoma skin cancer. Do not take if you have been diagnosed with prostate cancer. Avoid taking with alcohol or products that cause drowsiness. Consult a health care practitioner prior to use if you are taking medications or natural health products. Consult a health care practitioner prior to use if you have a liver disorder, develop symptoms of liver trouble or symptoms of low estrogen (such as joint pain, mood changes, changes in libido, hot flashes, night sweats, vaginal dryness or irregular menstruations). Stop use and consult a health care practitioner if you develop liver-related symptoms (e.g. yellowing of the eyes and/or skin, dark urine, abdominal pain, jaundice) or symptoms of low estrogen. Consult a health care practitioner prior to use to exclude the diagnosis of a serious cause of hormonal imbalance.
Testo originale in inglese.
Scheda del prodotto
- Altri nomi
- Female Hormone Care Daily
- Titolare
- Red Maple Bio Inc.
- NPN o DIN-HM
- 80107320
- Stato
- Licenza attiva
- Data della licenza
- 15 gennaio 2021
- Data di revisione
- 6 febbraio 2025
- Forma
- Capsule
- Via di somministrazione
- Orale
- Tipo di domanda
- Non traditionnelle
Fonte
Scheda ufficiale Health Canada, licenza 80107320
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Testo originale in inglese.
Testo originale in francese.
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Avvertenze ufficiali (Health Canada)
Health Canada pubblica avvertenze su questi ingredienti:
- Vitex agnus-castus
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
CHASTE TREE - VITEX AGNUS-CASTUS
Via di somministrazione: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
Fonti citate da Health Canada (4)
- Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
Controindicazioni
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
Fonti citate da Health Canada (9)
- Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
- Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
- Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
- Actaea racemosa
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
Black Cohosh - Actaea Racemosa
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).
Fonti citate da Health Canada (6)
- Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause: the Journal of the North American Menopause Society 2004;11(5):575-577. PubMed Caso clinico
- EMA 2018: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). European Union Herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. March 2018. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
- EMA 2007: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) Annex 1. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root). London (UK): European Medicines Agency; May 20027. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf
- Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transplantation 2006;12(6):989-992. PubMed Caso clinico
- Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. New York (NY): Taylor and Francis; 2006.
- NIH 2004: National Institutes of Health. Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD): National Institutes of Health, Department of Health and Human Services; November 22, 2004. [Accessed 2024 December 3]. Available from: https://files.nccih.nih.gov/s3fs-public/news/blackcohosh_mtngsumm.pdf
Controindicazioni
Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).
Fonti citate da Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Tilgner S. Herbal Medicine from the Heart of the Earth Creswell (OR): Wise Acre Press; 1999.
- Withania somnifera
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
ASHWAGANDHA - WITHANIA SOMNIFERA
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Fonti citate da Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Fonti citate da Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.
Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).
Il prodotto è cambiato? Fotografi la confezione.
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.